Table 1.

[⁶⁷Ga]NeoBOMB1 biodistribution data, as % ID/g mean ± sd, n = 4; at 4 h pi in T-47D Xenograft-Bearing SCID Mice; results in 3 different NeoBOMB1 doses are included in each column, with 40 nmol administered for in vivo GRPR-blockade.

Tissue/Dose	10 pmol 1	200 pmol 2	40 nmol 3
Blood	0.53 ± 0.04	0.42 ± 0.06	0.46 ± 0.03
Liver	3.37 ± 0.19	6.50 ± 0.34	9.67 ± 0.75
Heart	0.26 ± 0.01	0.34 ± 0.04	0.38 ± 0.02
Kidneys	3.40 ± 0.45	2.76 ± 0.26	3.95 ± 0.94
Stomach	4.36 ± 0.56	2.38 ± 0.13	0.42 ± 0.10
Intestines	16.71 ± 2.18	15.13 ± 1.52	11.08 ± 2.71
Spleen	1.02 ± 0.09	0.70 ± 0.09	0.79 ± 0.11
Muscle	0.10 ± 0.03	0.12 ± 0.01	0.16 ± 0.06
Lungs	0.50 ± 0.06	0.43 ± 0.06	0.42 ± 0.02
Femur	0.58 ± 0.06	0.28 ± 0.01	0.31 ± 0.02
Pancreas	206.29 ± 17.35	42.46 ± 1.31	1.17 ± 0.11
Tumor	9.52 ± 2.15	7.79 ± 1.54	0.64 ± 0.10

¹ Corresponding to animal groups injected with a specific activity of 3.7 MBq/nmol; or ² 0.185 MBq/nmol; ³ in vivo GRPR-blockade mice group.